EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 183 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Dormant Tumor Cells Can Be Sensitized to Chemotherapy February 20, 2019 FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma June 25, 2020 ESMO Congress 2021, 16-21 September September 2, 2021 Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... May 21, 2019 Load more HOT NEWS Children with Acute Lymphoblastic Leukemia Can Skip Radiation to the Brain Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and...
